

Supplemental Table and Figures:

Supplemental Table 1. Association of concordant and discordant performance-based functional assessments and outcomes

	<u>Discordant</u>			<u>Concordant</u>		
	SPPB High M3SE Low	SPPB Low M3SE High	p-value	SPPB High M3SE High	SPPB Low M3SE Low	p-value
Participants n (% of 350)	81 (23.1)	61 (17.4)	--	116 (33.1)	92 (26.3)	--
ESKD n (% of group)	7 (8.6)	8 (13.1)	0.417	13 (11.2)	13 (14.1)	0.554
Death	9 (11.1)	9 (14.8)	0.546	11 (9.5)	27 (29.3)**	0.0009
ESKD or 50% reduction GFR	8 (9.8)	13 (21.3)	0.794	13 (11.2)	18 (19.6)	0.121
ESKD, 50% reduction GFR, or death	17 (21.0)	21 (34.4)	0.125	24 (20.7)	44 (47.8)**	0.0007
	IADL High M3SE Low	IADL Low M3SE High	p-value	IADL High M3SE High	IADL Low M3SE Low	p-value
Participants n (% of 350)	106 (30.3)	37 (10.6)	--	140 (40.0)	67 (19.1)	--
ESKD n (% of group)	14 (13.2)	3 (8.1)	0.439	18 (12.9)	6 (9.0)	0.441
Death	16 (15.1)	4 (10.8)	0.549	16 (11.4)	20 (29.9)**	0.003
ESKD or 50% reduction GFR	19 (17.9)	3 (8.1)	0.19	23 (16.4)	7 (10.4)	0.29
ESKD, 50% reduction GFR, or death	34 (32.1)	7 (18.9)	0.198	38 (27.1)	27 (40.3)	0.114
	SPPB High IADL Low	SPPB Low IADL High	p-value	SPPB High IADL High	SPPB Low IADL Low	p-value
Participants n (% of 350)	34 (9.7)	83 (23.7)	--	163 (46.6)	70 (20.0)	--
ESKD n (% of group)	3 (8.8)	15 (18.1)	0.249	17 (10.4)	6 (8.6)	0.679
Death	4 (11.8)	16 (19.3)	0.372	16 (9.8)	20 (28.6)**	0.00084
ESKD or 50% reduction GFR	3 (8.8)	24 (28.9)*	0.04	18 (11.0)	7 (10.0)	0.824
ESKD, 50% reduction GFR, or death	7 (20.6)	38 (45.8)*	0.046	34 (20.9)	27 (38.6)*	0.0154

Note: P-values compares two groups listed side by side

* indicates significance p≤0.05

**indicates significance p≤0.001

Supplemental Table 2. "Performance-based Functional Assessment Hazard Ratios accounting for competing risk of death, ESKD or 50% decline GFR"

	Death		ESKD or 50% Decline GFR	
	CPH	FG	CPH	FG
SPPB	2.43 (1.36-4.34)	2.403 (1.397 - 4.134)	1.36 (0.72 – 2.55)	1.197 (0.589 - 2.433)
M3SE	1.49 (0.80 – 2.77)	1.429 (0.809 - 2.523)	1.03 (0.55 – 1.93)	0.963 (0.510 - 1.819)
IADL	1.71 (0.97 – 2.99)	1.747 (1.028 - 2.968)	0.49 (0.24-1.00)	0.426 (0.198 – 0.918)
Summary Score	2.07 (1.16-3.69)	2.052 (1.243 - 3.387)	0.85 (0.46 – 1.59)	0.734 (0.384 - 1.405)

CPH = Cox Proportional Hazard


FG = Fine and Gray

Supplemental Table 3. Comparative utility of performance-based functional assessments and summary score using Cox-Regression analysis


		Death				ESKD				ESKD or 50% decline GFR				ESKD, 50% decline GFR, or death			
		P-value	HR (95% CI)	-2 Log Likelihood	Chi-squared	P-value	HR (95% CI)	-2 Log Likelihood	Chi-squared	P-value	HR (95% CI)	-2 Log Likelihood	Chi-squared	P-value	HR (95% CI)	-2 Log Likelihood	Chi-squared
	Unadjusted Model	--	--	591.40		--	--	420.63	--	--	--	561.16	--	--	--	1127.03	--
	Adjusted Model	--	--	569.53	21.87	--	--	352.74	67.89	--	--	487.10	74.07	--	--	1063.14	63.89
1	Adjusted	--	--	569.53	21.87	--	--	352.74	67.89	--	--	487.10	74.07	--	--	1063.14	63.89
	SPPB	0.003	2.43 (1.36 - 4.34)	560.12	9.41	0.423	0.74 (0.36 - 1.54)	352.09	0.65	0.342	1.36 (0.72 - 2.55)	486.19	0.91	0.002	1.96 (1.28 - 2.99)	1053.26	9.88
2	SPPB	0.004	2.34 (1.31 - 4.21)	--	--	0.398	0.73 (0.35 - 1.52)	--	--	0.344	1.36 (0.72 - 2.56)	--	--	0.002	1.93 (1.26 - 2.94)	--	--
	M3SE	0.419	1.30 (0.69 - 2.44)	559.46	0.66	0.568	1.23 (0.60 - 2.50)	351.77	0.32	0.972	1.01 (0.54 - 1.90)	486.19	0.00	0.461	1.18 (0.76 - 1.84)	1052.72	0.54
	SPPB	0.010	2.19 (1.21 - 3.99)	--	--	0.649	0.84 (0.39 - 1.78)	--	--	0.112	1.69 (0.88 - 3.24)	--	--	0.001	2.04 (1.31 - 3.15)	--	--
3	M3SE	0.496	1.25 (0.66 - 2.36)	--	--	0.483	1.29 (0.63 - 2.65)	--	--	0.765	1.10 (0.58 (2.08))	--	--	0.398	1.21 (0.78 - 1.89)	--	--
	IADL	0.271	1.39 (0.77 - 2.48)	558.27	1.19	0.197	0.59 (0.27 - 1.31)	350.00	1.77	0.020	0.42 (0.20 - 0.87)	480.11	6.08	0.310	0.80 (0.51 - 1.24)	1051.67	1.05
	Summary Score	0.013	2.07 (1.16 - 3.69)	563.34	6.20	0.562	0.81 (0.39 - 1.66)	352.40	0.34	0.621	0.85 (0.46 - 1.59)	486.85	0.26	0.126	1.39 (0.91 - 2.10)	1060.81	2.33

Note: Adjusted model includes baseline values for: Age, Gender, Race, BMI, MAP, baseline GFR, Diabetes, CVD, Cancer, Education, and Income

Supplemental Figure 1. ESKD



Supplemental Figure 2. ESKD or 50% decline GFR



Supplemental Figure Legend

Figures 1-2: Kaplan-Meier plots of high performance (bolded line) versus low performance groups (non-bolded line) for (A) SPPB, (B) M3SE, (C) IADL, and (D) Summary Score for outcomes of (1) end-stage kidney disease; (2) 50% reduction in GFR or ESKD. Log-rank statistic p-value.